Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20644875 | 0.97 | — | — | |
| SCHEMBL14455130 | 0.94 | USP2 (0.31) | — | |
| SCHEMBL18821566 | 0.92 | — | — | |
| SCHEMBL24878964 | 0.90 | — | — | |
| SCHEMBL22849861 | 0.90 | NPSR1 (0.32) | — | |
| SCHEMBL17444943 | 0.90 | NPSR1 (0.32) | — | |
| SCHEMBL15095836 | 0.89 | NPSR1 (0.31) | — | |
| SCHEMBL1107069 | 0.88 | — | — | |
| SCHEMBL19430762 | 0.87 | NPSR1 (0.32) | — | |
| SCHEMBL18743200 | 0.86 | NPSR1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400497-A1 | 3CLPRO PROTEASE INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-07-17 | — | — | EP | disclosed |
| WO-2022148354-A1 | POLYCYCLIC KINASE INHIBITOR | 山东轩竹医药科技有限公司 | 2022-07-14 | — | — | WO | disclosed |
| EP-3753941-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Blueray Biopharma Co., Ltd. (CN) | 2020-12-23 | — | — | EP | disclosed |
| WO-2019158019-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海青煜医药科技有限公司 | 2019-08-22 | — | — | WO | disclosed |
| EP-2283004-B1 | AMIDO-THIOPHENE COMPOUNDS AND THEIR USE | UNIV EDINBURGH (GB) | 2015-05-27 | — | — | EP | disclosed |
| US-8362008-B2 | Amido-thiophene compounds and their use as 11-beta-HSD1 inhibitors | THE UNIVERSITY OF EDINBURGH (GB) | 2013-01-29 | — | — | US | disclosed |
| US-20130012545-A1 | Amido-Thiophene Compounds and Their Use | THE UNIVERSITY OF EDINBURGH (GB) | 2013-01-10 | — | — | US | disclosed |
| US-8299063-B2 | Amido-thiophene compounds and their use | THE UNIVERSITY OF EDINBURGH (GB) | 2012-10-30 | — | — | US | disclosed |
| WO-2011058149-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-05-19 | — | — | WO | disclosed |
| WO-2010146338-A1 | AMIDO-ISOTHIAZOLE COMPOUNDS AND THEIR USE AS INHIBITORS OF 11BETA-HSD1 FOR THE TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | THE UNIVERSITY OF EDINBURGH (GB) | 2010-12-23 | — | — | WO | disclosed |
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | THE UNIVERSITY OF EDINBURGH | 2010-10-21 | — | — | US | disclosed |
| WO-2009112845-A1 | AMIDO-THIOPHENE COMPOUNDS AND THEIR USE | THE UNIVERSITY OF EDINBURGH (GB) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009074789-A1 | AMIDO-THIOPHENE COMPOUNDS AND THEIR USE AS 11-BETA-HSD1 INHIBITORS | THE UNIVERSITY OF EDINBURGH (GB) | 2009-06-18 | — | — | WO | disclosed |
| US-7304052-B2 | Substituted homopiperidinyl benzimidazole analogues as fundic relaxants | JANSSEN PHARMACEUITCA N.V. (BE) | 2007-12-04 | — | — | US | disclosed |
| US-7304052-B2 | Substituted homopiperidinyl benzimidazole analogues as fundic relaxants | JANSSEN PHARMACEUITCA N.V. (BE) | 2007-12-04 | — | — | US | disclosed |
| US-20070155713-A1 | Nitrogen-containing heterocyclic compounds and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155713-A1 | Nitrogen-containing heterocyclic compounds and use thereof | NNMT, HLA-DRB1, NNT | OPRD1 3135/4885CYP1A2 1479/4885 |
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | HSD11B1, HSD11B2, HSD17B1 | OPRD1 1721/4885CYP1A2 145/4885 |
| US-20130012545-A1 | Amido-Thiophene Compounds and Their Use | HSD11B1, HSD11B2, HSD17B1 | OPRD1 1976/4885CYP1A2 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.